Professor Yong-Jie Lu

MBBS, MD, PhD
Professor of Molecular Oncology
Group Leader
Research Focus

We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular for prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.

Key Publications

The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res (2017) 23(17):5112-5122. PMID: 28615267

Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS ONE (2015) 10(9): e0138032. PMID: 26397728

DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet (2015) 15;24(4):963-71. PMID: 25281662

Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014) 232(5):566-77. PMID: 24407904

Major Funding
  • 2017-2018- Angle Europe PLC, "The prognostic value of circulating megakaryocytes for cancer patients" £201,685
  • 2015-2018- The Orchid Cancer Appeal, "Circulating tumour cell study and biomarker identification in prostate cancer" £485,000
Other Activities
  • Senior Editor: American Journal of Cancer Research
  • Member of prostate cancer ICGC consortium
  • Member of PRACTICAL prostate cancer predisposition study international consortium. 
Research

I have set up a research team devoted to cancer genetic studies and biomarker development, in particular in male urological cancers. The mission of the research team is to reduce motility and morbidity of cancer patients by understanding cancer development and progression mechanisms and facilitating precision medicine through the development of efficient cancer detection, prognostic and treatment response prediction/monitoring biomarkers.

Our past work have been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, our research work moved into circulation biomarker development, including CTCs, exosome and other cells, for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.

There are currently two main research areas of interest:

  • Biomarker discovery and clinical applications, focusing on circulating biomarkers (CTCs, exosomes and other cancer associated circulating cells) for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.
  • Mechanisms of prostate cancer metastasis and therapeutic resistance.
Other Activities
  • Senior Editor: American Journal of Cancer Research
  • Editorial Board Member: The Open Breast Cancer Journal
  • Editorial Board Member: Journal of Cancer Research Updates
  • Scientific assessment committee member: France national cancer research programme Canceropole (2007-2014)
  • Research grant reviewer for funding bodies, such as British Medical Research Council (MRC), British National Institute for Health Research (NIHR), UK Prostate Action, Prostate Cancer Research Charity, National Cancer Institute of France, International Association of Cancer Research, Hong Kong Research Grants Council
  • Referee of scientific journals such as Oncogene, J Path, Gene Chromosome Cancer, Br J Cancer, International J Cancer, Carcinogenesis, PloS One, BMC Cancer, Histopathology, Clinical Cancer Research and America Journal of Pathology
  • Member of prostate cancer ICGC consortium
    Member of PRACTICAL prostate cancer predisposition study international consortium
  • Active Member of American Association for Cancer Research
  • Honorable Professor, Second Military Medical University, Shanghai, China
  • Honorable Professor, Naning Medical University, China
  • Visiting Professor, Zhengzhou University Medical College, China
Major Funding
  • 2017-2018- Angle Europe PLC, "The prognostic value of circulating megakaryocytes for cancer patients" £201,685
  • 2015-2018- The Orchid Cancer Appeal, "Circulating tumour cell study and biomarker identification in prostate cancer" £485,000
  • 2014-2018- Medical Research Council, Associated genes in prostate cancer, £303,225

Recent Publications

Erratum to: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (Nature Communications, (2018), 9, 1, (1340), 10.1038/s41467-018-03178-z) Vijayakrishnan J, Studd J, Broderick P et al. Nature Communications (2019) 10(7)

Erratum to: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (Nature Communications, (2017), 8, 1, (1892), 10.1038/s41467-017-00320-1) Sud A, Thomsen H, Law PJ et al. Nature Communications (2019) 10(7)

Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1) Matejcic M, Saunders EJ, Dadaev T et al. Nature Communications (2019) 10(7)

Erratum to: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (Nature Communications, (2018), 9, 1, (3707), 10.1038/s41467-018-04989-w) Went M, Sud A, Försti A et al. Nature Communications (2019) 10(7)

Erratum to: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (Nature Communications, (2018), 9, 1, (4079), 10.1038/s41467-018-06302-1) Mancuso N, Gayther S, Gusev A et al. Nature Communications (2019) 10(7)

Reply by Authors. Xu L, Mao X, Grey A et al. J Urol (2019) (2) 10109701JU0000602796
https://www.ncbi.nlm.nih.gov/pubmed/31580196

Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches Song D, Powles T, Shi L et al. Journal of Pathology (2019) 249(7) 151-165

Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. Xu L, Mao X, Grey A et al. The Journal of Urology 203(1) 101097JU000000000000-101097JU000000000000
https://www.ncbi.nlm.nih.gov/pubmed/31389764

Observation of Light-by-Light Scattering in Ultraperipheral Pb+Pb Collisions with the ATLAS Detector Aad G, Abbott B, Abbott DC et al. Physical Review Letters (2019) 123(7)

Comparison of Fragmentation Functions for Jets Dominated by Light Quarks and Gluons from pp and Pb+Pb Collisions in ATLAS. Aaboud M, Aad G, Abbott B et al. Physical Review Letters (2019) 123(1) 042001-042001
https://www.ncbi.nlm.nih.gov/pubmed/31491254

For additional publications, please click here
Team

Postdoctoral Researchers
Xueying Mao, Elzbieta Stankiewicz

PhD Students
Tanyu Guo, Caitlin Davis, Yeuzhou Zhang

Research Technician
Edwina Burke

Biography

Education

  • 1992-1995: Ph.D. student in Chinese Academy of Medical Sciences (CAMS) &  Peking Union Medical College (PUMC), Beijing. (Pathophysiology)
  • 1989-1992: Post-graduate student in Dept. of Biology, Harbin Medical University. (M.D. Medical Genetics.)
  • 1984-1989: Undergraduate medical student in Faculty of Medicine, Henan Medical University.

Appointments

  • Oct 2017-present: Professor of Molecular Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
  • July 2010-Sept 2017: Reader (Team Leader), Barts Cancer Institute, Barts and London School of Medicine and Dentistry, Queen Mary University of London (QMUL)
  • Jun 2003-July 2010: Senior Lecturer (Team Leader), Barts Cancer Institute, Barts and London School of Medicine and Dentistry, QMUL.
  • Oct 2001-Jun 2003: Research Associate (deputy Team Leader), Molecular Cytogenetics Laboratory, The Institute of Cancer Research (ICR), Sutton, UK.
  • Apr 2000-Oct. 2001: Senior postdoctoral scientist, Molecular Cytogenetics Laboratory, Section of Paediatrics (joint with Section of Molecular Carcinogenesis), ICR, Sutton, UK.
  • Apr 1997-Apr 2000: Postdoctoral scientist, Molecular Cytogenetics Laboratory, Section of Cell Biology & Experimental Pathology, ICR, Sutton, UK.
  • Oct 1995-Jan 1997: Visiting Scholar, Molecular Cytogenetics Laboratory, ICR, Sutton, UK.
Upcoming Events
  1. Thursday Seminar Series – Dr Benjamin Werner

    November 21 @ 12:30 pm - 1:30 pm
  2. Miltenyi Biotec Exhibition – Friday 22nd November 2019

    November 22 @ 9:00 am - 1:00 pm
© 2013 ~ 2019 Cancer Research UK Barts Centre